Product/ Company Information:
Description of Offer
Our cell therapy product, called PLX-R18, is designed to stimulate the regeneration of damaged bone marrow to produce blood cells lineages following exposure to high levels of radiation, thus preventing lethal hematological damage following exposure while providing regeneration capabilities to the bone marrow.
In addition to potential treatment, we have collaborated with the U.S. Department of Defense to study PLX-R18 as a prophylactic (preventive) treatment for radiation exposure, relevant to first responders, demonstrating 50-70% increase in survival rates.
Our company is also working with Fukushima Medical university since 2015, showing promising
data of PLX-R18 in increased survival rates and mitigating severe intestinal damage following
We would like to suggest a discussion to further introduce the product and its efficacy in mitigating radiation damage.
Interested in doing business in: Philippines
Activity: Joint Ventures: Cell Therapy Product